Posts

Spotlight On #HTGS26: Agentic AI and Digital Endpoints Supercharging R&D

on
HTGS26 is a prominent pharma tech conference highlighting advancements in R&D through agentic AI and digital endpoints. Agentic AI refers to autonomous AI systems capable of independent decision-making to accelerate drug discovery and development. Digital endpoints leverage real-world data and sensors for more efficient, patient-centric clinical trials. The event features keynotes on how these technologies reduce R&D timelines and costs by up to 30-50%. Recent sessions (early March 2026) showcased case studies from leading biopharma companies implementing these innovations. Organized by HTG, it draws 5,000+ attendees focusing on transforming the 'D' in R&D. Sources:

Esperion Therapeutics Acquires Corstasis for $75M Upfront to Gain Enbumyst Nasal Spray for Edema

on

Hims Pharmacy Partner Plans to Reintroduce GLP-1 Pill Pulled from Market Amid Regulatory Backlash

on

Moderna Agrees to Pay Up to $2.25 Billion to Settle COVID-19 Vaccine Patent Dispute with Arbutus and Roivant Subsidiary Genevant

on

FDA Fully Lifts Clinical Hold on Intellia Therapeutics' CRISPR Gene Therapy Trials for ATTR Amyloidosis

on

Prime Medicine Reverses Course, Seeks FDA Approval for Gene Therapy in CGD After Shelving

on

FDA Accelerates Rare Disease Drug Approvals with New Frameworks and Record 2025 Approvals

on

3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations

on

Orca Bio Presents Clinical Data on High-Precision Cell Therapies at 52nd EBMT Annual Meeting

on

Neko Health Appoints Dr. Sunita Mishra as Chief Medical Officer

on

Celldex Reports Strong Retreatment Results With Barzolvolimab In Cold Urticaria and Symptomatic Dermographism

on

North Carolina Exits Job Development Investment Grants for Two Gene Therapy Companies in Durham

on

UniQure's Huntington's Gene Therapy AMT-130 Faces FDA Roadblock, Requiring New Trial

on